| Cash and cash equivalents |
58.88M |
| Marketable securities |
0 |
| Proceeds from sale of RXi, received January 6, 2011 |
| Receivable |
108.35K |
| Investment in Adventrx Pharmaceuticals, at market |
| Income taxes recoverable |
| Interest receivable |
| Prepaid expenses and other current assets |
2.62M |
| Total current assets |
61.6M |
| Equipment and furnishings, net |
2.07M |
| Goodwill |
183.78K |
| Other assets |
54.65K |
| Total assets |
63.91M |
| Accounts payable |
4.82M |
| Accrued expenses and other current liabilities |
5.05M |
| Warrant liabilities |
6.69M |
| Total current liabilities |
20.11M |
| Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding |
0 |
| Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively |
96.94K |
| Additional paid-in capital |
431.69M |
| Accumulated comprehensive income, net of tax |
| Treasury stock, at cost (633,816 shares) |
| Accumulated deficit |
-408.19M |
| Total stockholders' equity |
23.6M |
| Total liabilities and stockholders' equity |
63.91M |
